Protagonist Therapeutics Inc logo

PTGX

Protagonist Therapeutics Inc

$7.51

Earnings Summary

Revenue
$0Mn
Net Profits
$-7.08Mn
Net Profit Margins
-Inf%

Highlights

Revenue:

Protagonist Therapeutics Inc’s revenue jumped NaN% since last year same period to $0Mn in the Q3 2016. On a quarterly growth basis, Protagonist Therapeutics Inc has generated NaN% jump in its revenue since last 3-months.

Net Profits:

Protagonist Therapeutics Inc’s net profit fell -105.39% since last year same period to $-7.08Mn in the Q3 2016. On a quarterly growth basis, Protagonist Therapeutics Inc has generated 0.2% jump in its net profits since last 3-months.

Net Profit Margins:

Protagonist Therapeutics Inc’s net profit margin jumped NaN% since last year same period to -Inf% in the Q3 2016. On a quarterly growth basis, Protagonist Therapeutics Inc has generated NaN% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Protagonist Therapeutics Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.8
EPS Estimate Current Year
-0.8

Highlights

EPS Estimate Current Quarter:

Protagonist Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.8 - a 12.03% jump from last quarter’s estimates.

EPS Estimate Current Year:

Protagonist Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.8.

Key Ratios

Key ratios of the Protagonist Therapeutics Inc post its Q2 2022 earnings

Earning Per Share (EPS)
-0.84
Return on Assets (ROA)
-0.25
Return on Equity (ROE)
-0.45

Highlights

Earning Per Share (EPS):

Protagonist Therapeutics Inc’s earning per share (EPS) fell -21.74% since last year same period to -0.84 in the Q2 2022. This indicates that the Protagonist Therapeutics Inc has generated -21.74% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Protagonist Therapeutics Inc’s return on assets (ROA) stands at -0.25.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Protagonist Therapeutics Inc’s return on equity (ROE) stands at -0.45.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-05
-0.54
-0.43
20.36%
2022-08-04
-0.94
-0.84
10.19%

Company Information

Protagonist Therapeutics is a clinical stage biopharmaceutical company with multiple peptide-based new chemical entities in different stages of development. Rusfertide (PTG-300) is an injectable hepcidin mimetic in a Phase 2 proof-of-concept clinical trial for polycythemia vera, and a separate Phase 2 clinical study for hereditary hemochromatosis. PN-943 is an orally delivered, gut-restricted alpha-4-beta-7 integrin specific antagonist peptide in a 150 patient Phase 2 study for the potential treatment of inflammatory bowel disease, with ulcerative colitis as the initial targeted indication. PTG-200 is an orally delivered, gut-restricted, interleukin-23 receptor specific antagonist peptide in a Phase 2 clinical trial for Crohn's disease. Two additional second-generation oral interleukin-23 receptor antagonist candidates PN-235 and PN-232, are in early stages of clinical development. The Company has developed a proprietary technology platform to discover and develop novel peptide-based therapeutics to address significant unmet medical needs and transform existing treatment paradigms.

Organisation
Protagonist Therapeutics Inc
Headquarters
7707 Gateway Boulevard, Newark, CA, United States, 94560-1160
Employees
118
Industry
Health Technology

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*